Skip to main content
SpringerLink
Log in

DIABETES

Two drugs are better than one to start T2DM therapy

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Early and intensive glycaemic control protects patients with type 2 diabetes mellitus (T2DM) from the development of late cardiovascular complications. The authors of the VERIFY trial now show that a more durable attainment of HbA1c <7% is observed by adding vildagliptin to metformin as starting therapy in newly diagnosed patients with T2DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Proposal for merging the glucocentric and the cardiocentric view of T2DM treatment.

References

  1. [No authors listed.] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).

  2. Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).

    Article  CAS  Google Scholar 

  3. Laiteerapong, N. et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care 42, 416–426 (2019).

    Article  CAS  Google Scholar 

  4. Brown, J. B., Conner, C. & Nichols, G. A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 33, 501–506 (2010).

    Article  CAS  Google Scholar 

  5. Phung, O. J. et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes. Metab. 16, 410–417 (2014).

    Article  CAS  Google Scholar 

  6. Matthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394, 1519–1529 (2019).

    Article  CAS  Google Scholar 

  7. Schnell, O. et al. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc. Diabetol. 18, 30 (2019).

    Article  Google Scholar 

  8. Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669–2701 (2018).

    Article  Google Scholar 

  9. Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehz486 (2019).

  10. Abdul-Ghani, M. & DeFronzo, R. A. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care 40, 1121–1127 (2017).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the Italian Ministry of Health (Ricerca Corrente), who supported part of this work.

Author information

Authors and Affiliations

  1. Department of Cardiovascular and Dysmetabolic Diseases, IRCCS MultiMedica, Milano, Italy

    Francesco Prattichizzo, Lucia La Sala & Antonio Ceriello

Authors
  1. Francesco Prattichizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucia La Sala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Ceriello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Ceriello.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prattichizzo, F., La Sala, L. & Ceriello, A. Two drugs are better than one to start T2DM therapy. Nat Rev Endocrinol 16, 15–16 (2020). https://doi.org/10.1038/s41574-019-0294-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-019-0294-3

  • Springer Nature Limited

This article is cited by

Search

Navigation